Repare Therapeutics Inc
RPTX
View Detailed Chart
2.650USD
0.0000.00%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
113.91MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
0.00%
1 Month
+3.11%
6 Months
+73.20%
Year to Date
+1.92%
1 Year
+112.00%
View Detailed Chart
TradingKey Stock Score of Repare Therapeutics Inc
Currency: USD Updated: 2026-01-27Key Insights
Repare Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 105 out of 394 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.00.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Repare Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Repare Therapeutics Inc Highlights
StrengthsRisks
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
Growing
The company is in a growing phase, with the latest annual income totaling USD 53.48M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 53.48M.
Fairly Valued
The company’s latest PE is -1.57, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 24.73M shares, decreasing 27.95% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 724.16K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.68.
Analyst Rating
Based on
0
analysts
--
Current Rating
3.000
Target Price
+13.21%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Repare Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Repare Therapeutics Inc Info
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
Ticker SymbolRPTX
CompanyRepare Therapeutics Inc
CEOForte (Steve)
Websitehttps://www.reparerx.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69305.530
-664.600 (-0.95%)
282.580
+22.390 (+8.61%)
2047.880
-3.850 (-0.19%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
